Welcome to our dedicated page for Endra Life Sciences news (Ticker: NDRA), a resource for investors and traders seeking the latest updates and insights on Endra Life Sciences stock.
ENDRA Life Sciences Inc. (NDRA) is an imaging technology company developing the Thermo Acoustic Enhanced UltraSound (TAEUS®) platform, with a primary focus on liver fat quantification for steatotic liver disease (SLD) and metabolic dysfunction‑associated steatohepatitis (MASH). News about ENDRA frequently centers on clinical data, regulatory planning and strategic shifts that affect how its technology may be used in metabolic disease management and drug development.
Recent press releases highlight feasibility and pilot study results in which ENDRA’s thermo‑acoustic fat fraction (TAFF) measurements are compared with MRI‑PDFF, the recognized imaging gold standard for liver fat. These updates provide details on statistical agreement across the SLD spectrum, performance at clinically important liver fat thresholds, and the implications for patient stratification and monitoring in MASLD/MASH and GLP‑1 trials. Investors and clinicians can follow how enhancements to TAEUS Liver’s probe design and algorithms are expected to improve accuracy and repeatability ahead of a planned De Novo pivotal study.
ENDRA news also covers its evolving go‑to‑market strategy, including a pivot toward metabolic disease and GLP‑1 therapy management, identification of key customer segments such as pharmaceutical companies, CROs and metabolic clinics, and plans for a subscription‑based access model. In parallel, the company issues updates on its digital asset treasury (DAT) strategy, including private placements, HYPE token purchases, and staking initiatives managed by Arca Investment Management with custody by Anchorage Digital Bank.
By following NDRA news on this page, readers can track clinical milestones, regulatory interactions, capital markets activity, and developments in ENDRA’s DAT program, all of which shape the company’s trajectory in both medical imaging and digital asset management.
ENDRA Life Sciences Inc. (NASDAQ:NDRA) announced the issuance of two U.S. patents related to its Thermo Acoustic Enhanced UltraSound (TAEUS®) technology. The patents include the '624 patent, which enhances TAEUS probe functionality, and the '163 patent, which protects the design of its thermoacoustic imaging probe. Both patents aim to improve diagnostic capabilities for conditions like Non-Alcoholic Fatty Liver Disease (NAFLD), affecting over 1 billion globally. ENDRA also highlighted its growing intellectual property portfolio, now at 85 assets, and ongoing clinical partnerships, especially with GE Healthcare.
ENDRA Life Sciences (NASDAQ:NDRA) will present its Thermo Acoustic Enhanced Ultrasound (TAEUS™) technology at the AIUM Annual Integrative Ultrasound Meeting on April 14, 2021, at 11:45 am ET. The presentation, led by CTO Michael Thornton, will overview TAEUS and its application in measuring liver fat, targeting conditions like Non-Alcoholic Fatty Liver Disease (NAFLD) affecting over one billion people worldwide. ENDRA will also showcase its TAEUS liver system in a virtual booth from April 11 to April 25.
ENDRA Life Sciences (NASDAQ:NDRA) reported its financial results for Q4 and FY 2020, with a net loss of $2.3 million ($0.10/share) in Q4, down from $4.8 million in 2019. Total operating expenses decreased to $2.3 million from $3.1 million in Q4 2019. For the full year, net loss was $11.7 million ($0.63/share), improved from $13.3 million in 2019. The company secured partnerships and clinical studies in Europe, strengthened its intellectual property, and raised $18.5 million through stock sales. A call to discuss results was scheduled for 4:30 PM ET today.
ENDRA Life Sciences (NASDAQ:NDRA) has partnered with Hepion Pharmaceuticals (NASDAQ:HEPA) to integrate its innovative TAEUS technology into Hepion's Phase 2b trial for CRV431, targeting non-alcoholic steatohepatitis (NASH). This collaboration aims to enhance patient screening and biomarker measurement, providing a cost-effective and non-invasive method for liver fat assessment. Positive topline data has been reported from Hepion's Phase 2a AMBITION trial, with patient enrollment for the Phase 2b study set to commence in late 2021, signaling advancements in liver disease treatments.
ENDRA Life Sciences Inc. (NASDAQ:NDRA) will report its fourth quarter 2020 financial results on March 25, 2021, after market close. A conference call and webcast are scheduled for 4:30 p.m. Eastern time, allowing management to discuss the financial results and recent corporate updates. The company is known for its Thermo Acoustic Enhanced UltraSound (TAEUS) technology, aimed at diagnosing chronic liver conditions affecting over 1 billion people globally. The details for participation and access to a replay are included in the press release.
ENDRA Life Sciences Inc. (NASDAQ:NDRA) will participate in two upcoming virtual investment conferences. The H.C. Wainwright Global Life Sciences Virtual Conference is scheduled for March 9-10, 2021, where management will give a presentation and hold one-on-one meetings. A recorded presentation will be available on demand from March 9, 2021. The 33rd Annual ROTH Conference will take place from March 15-19, 2021, with similar opportunities. ENDRA develops the Thermo Acoustic Enhanced UltraSound (TAEUS®) technology, aiming to improve liver health diagnostics.
ENDRA Life Sciences Inc. (NASDAQ:NDRA) has announced a new clinical study partnership with Inselspital University Hospital in Bern, Switzerland, focusing on the TAEUS ultrasound device for assessing Non-Alcoholic Fatty Liver Disease (NAFLD). This collaboration marks ENDRA's third clinical research partnership in Europe and aims to validate TAEUS as a non-invasive alternative to more invasive diagnostic techniques, involving 75 patients. The study data will enhance clinical evidence for TAEUS as commercialization efforts advance in Europe, alongside a recent collaboration renewal with GE Healthcare.
ENDRA Life Sciences (NASDAQ:NDRA) has been awarded U.S. Patent 10898166, enhancing its Thermo Acoustic Enhanced UltraSound (TAEUS®) technology. This patent focuses on systems for imaging biological tissue structures, complementing prior patents and expanding ENDRA's intellectual property (IP) portfolio to 80 assets. The company aims to apply TAEUS® in critical areas like Non-Alcoholic Fatty Liver Disease (NAFLD). With ongoing clinical partnerships and a commercial launch planned, ENDRA is positioning TAEUS® as a cost-effective alternative to MRI for liver condition diagnostics.
ENDRA Life Sciences Inc. (NASDAQ:NDRA) has been granted its 13th U.S. patent, number 10888898, for its Thermo Acoustic Enhanced UltraSound (TAEUS®) technology, which offers enhanced imaging capabilities for diagnosing Non-Alcoholic Fatty Liver Disease (NAFLD). This patent solidifies intellectual property protection in a market where NAFLD affects 30% of the U.S. population. ENDRA's commercial launch plans include establishing international research partnerships, with recent installations in major hospitals. The company continues to expand its patent portfolio, now totaling 78 assets.
ENDRA Life Sciences Inc. (NASDAQ:NDRA) will present at the H.C. Wainwright Virtual BioConnect 2021 Conference from January 11-14, 2021. Chairman and CEO Francois Michelon will showcase the company's innovative Thermo Acoustic Enhanced UltraSound (TAEUS®) technology, which visualizes tissue at a fraction of the cost of MRI, aimed initially at assessing Non-Alcoholic Fatty Liver Disease (NAFLD). The presentation will be available on the company's website starting January 11 at 6:00 a.m. Eastern time and archived for 90 days.